Unilever Stock News

GSK racked up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, largely for antibody drug sotrovimab, as it beat quarterly forecasts in its first earnings report since rejecting a bid from Unilever for its consumer arm. The drugmaker also said it expected pandemic-related sales in 2022 to be at similar levels to 2021 but said these would contribute less to profit due to lower margins on its antibody treatment. GSK''s sotrovimab, developed with Vir Biotechnology, is one of the few COVID-19 treatments shown to have worked against the fast-spreading Omicron variant, spurring huge demand. It was amongst GSK''s top selling offerings in 2021. Sales of sotrovimab, or Xevudy, were 828 million pounds in the fourth quarter, up from 114 million in the third quarter and well above market expectations of 774 million pounds. Unilever won''t up £50bn offer for GSK-Pfizer unit Adjusted earnings for the British drugmaker stood at 25.6 pence per share for the three months to Dec. 31, while turnover rose 13% to 9.53 billion pounds at constant currency rates.

LONDON, Feb 9 ― GSK racked up £1.4 billion (RM7.94 billion) in Covid-related sales in 2021, largely for antibody drug sotrovimab, as it beat quarterly forecasts in its first earnings report since rejecting a bid from Unilever for its consumer…

(Reuters) GSK racked up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, largely for antibody drug sotrovimab, as it beat quarterly forecasts in its first earnings report since rejecting a bid from Unilever for its consumer arm.

In the current market session, Unilever Inc. (NYSE: UL ) is trading at $52.26, after a 0.1% gain. However, over the past month, the stock fell by 3.15%, and in the past year, by 3.69%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. The stock is currently higher its 52 week low by 13.44%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio Full story available on Benzinga.com

Cost control will be harder but it may help each business unit thrive

Fallout from failed GSK unit bid dogs board as company prepares for results presentation

Key Events This Week: All Eyes On The CPI After what DB''s Jim Reid describes as "a week for the ages" this week should be calmer until of course US CPI comes along on Thursday. As the Deutsche strategist notes, in his look back at a hell of a week, what made last week so fascinating was the rare interplay between macro and micro. Not only did the rates world shake and reverberate (2yr bunds +35.9bps and the worse week since 2008), but on successive days we saw the biggest market cap fall in history for any company (Meta), followed by the biggest rise ever (Amazon). We have 83 S&P 500 companies reporting this week but no Goliath sized ones, so it''ll be a more normal week for earnings. The macro and micro last week was enough to push the Russian/Ukraine tensions into the background but they are clearly still there so we have to watch out for that as well. Over the weekend ECB governor Knott (a hawk) became the first ECB official to confirm what we reported last week, when he endorsed a 2022 hike by suggesting that he expects a hike around Q4 and another in Spring 2023, and that they are most likely to be in 25bps increments.

Futures Tread Water Amid Peripheral Bond Rout As Key CPI Print Looms U.S. index futures swung around in a volatile, illiquid overnight session, and at last check were flat despite traders'' concerns about growing fireworks in the European bond market where Italian and Greek bond plunged amid fears of ECB rate hikes as soon as October, while waiting for Thursday''s key CPI data and further corporate earnings. S&P 500 futures were up 2 points or 0.05%, Nasdaq futures were up 26 points or 0.18% and Dow futures were up fractionally as markets now expect more than five quarter-point Federal Reserve interest-rate hikes in 2022 to keep inflation on check following a strong U.S. jobs report. Treasury yields and the dollar were stable, while the euro snapped a six-day strengthening run. WTI crude fell after last week''s rally. Chinese shares climbed on their return from a weeklong holiday. Bitcoin extended its recovery surge. In the premarket, Peloton was in focus, soaring 27% on reports it''s evaluating interest from potential suitors including Amazon and Nike.

Climate pledges about cutting emissions and reducing carbon by of the world's largest companies, including Amazon, GlaxoSmithKline PLC (LSE:GSK), Unilever PLC (LSE:ULVR) and Nestlé are not quite

UK pre-market stocks update Taylor Wimpey, Unilever, Vodafone, Amigo, Abrdn

Analysts expect some of Europe''s biggest companies to report forecast-beating earnings this week.

Top Unilever Plc (UL) shareholders are calling for the consumer goods company to make some major changes especially after its recent failed $68B bid for GlaxoSmithKline''s

Amazon, Ikea, Nestlé and others will fall sort of promise to cut carbon by 100%, says NewClimate Institute Some of the worlds biggest businesses are failing to live up toclaims they will hit net-zero emissions targets, according to research that suggests they will cut their carbon emissions by only 40% rather than the 100% cuts claimed. Household names such as Amazon, Ikea, Nestlé and Unilever are among the companies named as showing little substance to their claims that they will cut emissions drastically. Continue reading

London's financial calendar is a packed one next week, with BP, Ocado, GlaxoSmithKline, AstraZeneca, Unilever, British American Tobacco and Barratt among the names reporting. Although the trillion-do

Woke Capital Won''t Save The Planet But It Will Crash The Economy Submitted by Rupert Darwall, originally published in Real Clear Energy, Judged by BlackRock CEO Larry Finks latest letter , January 2022 might turn out to be the highwater mark of woke capitalism. Stakeholder capitalism is not woke, Fink says, because capitalism is driven by mutually beneficial relationships between businesses and their stakeholders. Hes right. What Fink describes is capitalism pure and simple, the stakeholder modifier adding nothing to the uniqueness of capitalism in harnessing competition and innovation for the benefit of all. Finks shift is more than rhetorical. Just three years ago, in his 2019 Profit and Purpose letter, Fink told CEOs that the $24 trillion of wealth Millennials expect to inherit from their Boomer parents meant that ESG (environment, social, governance) issues will be increasingly material to corporate valuations. Now Fink tells them that long-term profitability is the measure by which markets will determine their companies success, dumping the ESG valuation metrics hed previously championed.